

Table 11 **Central Serum Potassium (mEq/L) Change from Baseline to Week 12 by Baseline Serum Potassium (ITT Population)**

	Spironolactone + Placebo (N=148)			Spironolactone + Patiromer (N=147)		
	Baseline Central Serum Potassium 4.3-<4.7 mEq/L	Baseline Central Serum Potassium 4.7-<5.1 mEq/L	Overall	Baseline Central Serum Potassium 4.3-<4.7 mEq/L	Baseline Central Serum Potassium 4.7-<5.1 mEq/L	Overall
Baseline						
N	66	82	148	63	84	147
Mean (SD)	4.42 (0.220)	4.92 (0.321)	4.69 (0.374)	4.47 (0.287)	4.94 (0.271)	4.74 (0.360)
Median	4.45	4.90	4.70	4.50	4.90	4.70
Min, max	3.6, 5.3	3.8, 5.8	3.6, 5.8	3.8, 5.7	4.0, 5.8	3.8, 5.8
Change from baseline to Week 12						
N	64	76	140	62	82	144
Mean (SD)	0.40 (0.494)	0.03 (0.468)	0.20 (0.514)	0.16 (0.468)	-0.09 (0.442)	0.02 (0.469)
Median	0.35	0.0	0.20	0.10	-0.10	0.00
Min, max	-0.7, 1.6	-1.3, 1.0	-1.3, 1.6	-0.9, 1.7	-0.9, 1.7	-0.9, 1.7

Notes: Two baseline potassium subgroups, 4.3-<4.7 mEq/L versus 4.7-5.1 mEq/L, are based on central laboratory data. If a subject's serum potassium result is not in one of these two subgroups, the subject's potassium stratum at randomization was used.
ITT=Intent-to-treat; SD=Standard deviation.